Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bullish +35

Bristol Myers Squibb (BMY) Stock Could Be 13% Undervalued As Pipeline Plans Take Shape - simplywall.st

AI-generated analysis

📈 Bristol-Myers Squibb (BMY) shares are trading at $54.70 with a recent 30-day return of -8.01% but a 1-year total shareholder return of 22.41%.

💰 The company declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, to shareholders of record on July 2, 2026.

📊 The stock offers a current dividend yield of approximately 4.6% based on the latest share price.

🎯 Analysts estimate a fair value of $62.96, implying the stock is undervalued by roughly 13% or an intrinsic discount of 54.52%.

🔬 The company's late-stage pipeline and strategic partnerships with BioNTech and Philochem aim to offset patent expiries for key drugs like Eliquis and Opdivo.

⚖️ The current P/E ratio of 15.4x is slightly above the industry average of 14.9x but below a fair ratio of 18.6x and peer averages of 21.7x.

⚠️ Significant risks include patent cliffs for major brands, pressure on pricing and margins in the core U.S. market, and potential shifts in revenue mix.

Bullish Signals
  • The stock is estimated to be undervalued by approximately 13% with a fair value of $62.96 compared to the current price of $54.70.
  • A robust late-stage pipeline and strategic partnerships are expected to support future regulatory approvals and label expansions, helping offset patent expiries.
  • The company offers a solid 4.6% dividend yield with a declared quarterly payout of $0.63 per share.
  • The stock has delivered a strong 22.41% total shareholder return over the past year despite recent cooling momentum.
Risk Factors
  • The company faces meaningful risks from patent cliffs associated with key drugs like Eliquis and Opdivo.
  • Valuation metrics show mixed signals, with the current P/E ratio of 15.4x sitting above the industry average of 14.9x.
Full Analysis
Bristol-Myers Squibb (BMY) shares are trading at $54.70, reflecting a recent 30-day decline of 8.01% despite a 22.41% total shareholder return over the past year. The company recently declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, to shareholders of record on July 2, 2026, offering a yield of approximately 4.6%. Analysts at Simply Wall St estimate the stock's fair value at $62.96, suggesting it is undervalued by roughly 13%. This valuation gap is attributed to a robust late-stage pipeline, strategic partnerships with entities like BioNTech and Philochem, and potential for label expansions that could offset upcoming patent expiries for major brands such as Eliquis and Opdivo. Despite the bullish fair value estimate, the stock presents mixed signals regarding valuation metrics. The current P/E ratio of 15.4x sits slightly above the US pharmaceuticals industry average of 14.9x but remains below a calculated fair ratio of 18.6x and peer averages of 21.7x. Investors must weigh these potential upside drivers against significant risks including patent cliffs, pricing pressure in the core U.S. market, and shifting revenue mix dynamics.